Tarceva 150 mg Alternative – Erlonix (Erlotinib) 150 mg Tablet | Beacon Pharmaceuticals
Erlonix 150 mg (Erlotinib) Tablet by Beacon Pharmaceuticals. Reference brand: Tarceva. EGFR inhibitor; used in selected EGFR-mutated non-small cell lung cancer. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Erlonix 150 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Erlotinib. Tarceva is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Erlonix vs Tarceva – Reference Brand Comparison
Tarceva is a recognized reference brand associated with Erlotinib. Erlonix is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Erlonix. Active ingredient: Erlotinib. Strength: 150 mg. Dosage form: Tablet. Therapeutic class: EGFR inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Erlotinib is used in selected EGFR-mutated non-small cell lung cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Erlotinib Works
Erlotinib inhibits EGFR signaling. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 150 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Erlotinib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include skin rash, diarrhea and interstitial lung disease. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include skin rash, diarrhea and interstitial lung disease. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Erlonix Listed as an Alternative to Tarceva?
The comparison helps identify another listed brand containing Erlotinib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Erlonix. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Tarceva. Generic: Erlotinib. Strength: 150 mg. Dosage form: Tablet.
Frequently Asked Questions
What is Erlonix 150 mg? It is a tablet containing Erlotinib 150 mg according to the supplied Beacon price list. What is it used for? Erlotinib is used in selected EGFR-mutated non-small cell lung cancer, subject to specialist assessment. Can it replace Tarceva? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Erlotinib |
|---|---|
| Strength | 150 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Iressa 250 mg Alternative – Gefinix (Gefitinib) 250 mg Tablet | Beacon Pharmaceuticals
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Ositag (Osimertinib) 80 mg Tablet | Beacon Pharmaceuticals
Tarceva 100 mg Alternative – Erlonix (Erlotinib) 100 mg Tablet | Beacon Pharmaceuticals
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xalkori 250 mg Alternative – Crizocent (Crizotinib) 250 mg Capsule | Incepta Pharmaceuticals
Crizocent 250 mg (Crizotinib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Xalkori (Pfizer).
Pack: 12 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Reviews
There are no reviews yet.